Short Interest in Krystal Biotech, Inc. (NASDAQ:KRYS) Decreases By 13.5%

Krystal Biotech, Inc. (NASDAQ:KRYS) was the target of a significant decrease in short interest in February. As of February 28th, there was short interest totalling 2,760,000 shares, a decrease of 13.5% from the February 13th total of 3,190,000 shares. Approximately 11.2% of the company’s stock are short sold. Based on an average trading volume of 278,600 shares, the short-interest ratio is currently 9.9 days.

Insiders Place Their Bets

In other news, CAO Kathryn Romano sold 750 shares of the firm’s stock in a transaction that occurred on Thursday, February 27th. The stock was sold at an average price of $175.22, for a total value of $131,415.00. Following the transaction, the chief accounting officer now owns 12,604 shares in the company, valued at $2,208,472.88. This trade represents a 5.62 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Suma Krishnan sold 25,000 shares of the firm’s stock in a transaction that occurred on Thursday, March 13th. The shares were sold at an average price of $177.79, for a total value of $4,444,750.00. Following the completion of the transaction, the insider now owns 1,463,711 shares in the company, valued at $260,233,178.69. This represents a 1.68 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 14.10% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the business. California State Teachers Retirement System increased its holdings in Krystal Biotech by 5.9% during the 4th quarter. California State Teachers Retirement System now owns 20,388 shares of the company’s stock valued at $3,194,000 after purchasing an additional 1,127 shares during the period. Universal Beteiligungs und Servicegesellschaft mbH bought a new position in Krystal Biotech in the 4th quarter valued at approximately $3,634,000. GF Fund Management CO. LTD. bought a new position in Krystal Biotech in the 4th quarter valued at approximately $95,000. Palisades Investment Partners LLC lifted its position in Krystal Biotech by 9.3% in the 4th quarter. Palisades Investment Partners LLC now owns 40,479 shares of the company’s stock valued at $6,341,000 after acquiring an additional 3,436 shares in the last quarter. Finally, Woodline Partners LP lifted its position in Krystal Biotech by 23.0% in the 4th quarter. Woodline Partners LP now owns 221,102 shares of the company’s stock valued at $34,638,000 after acquiring an additional 41,287 shares in the last quarter. Hedge funds and other institutional investors own 86.29% of the company’s stock.

Krystal Biotech Stock Down 0.3 %

Shares of KRYS stock opened at $188.61 on Friday. The business has a 50-day moving average price of $165.98 and a two-hundred day moving average price of $173.80. Krystal Biotech has a 12-month low of $141.72 and a 12-month high of $219.34. The firm has a market cap of $5.43 billion, a P/E ratio of 63.08 and a beta of 0.87.

Krystal Biotech (NASDAQ:KRYS) last issued its quarterly earnings results on Monday, February 24th. The company reported $1.52 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.29 by $0.23. The firm had revenue of $91.10 million during the quarter, compared to analyst estimates of $91.35 million. Krystal Biotech had a return on equity of 11.41% and a net margin of 30.69%. The company’s revenue was up 116.4% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.30 earnings per share. As a group, research analysts expect that Krystal Biotech will post 6.14 EPS for the current fiscal year.

Analyst Ratings Changes

A number of brokerages recently commented on KRYS. Chardan Capital increased their price target on Krystal Biotech from $212.00 to $218.00 and gave the company a “buy” rating in a research report on Thursday, February 20th. HC Wainwright reaffirmed a “buy” rating and set a $221.00 price target on shares of Krystal Biotech in a research report on Friday, February 28th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $215.00 price target on shares of Krystal Biotech in a research report on Thursday, February 20th. Citigroup raised their target price on Krystal Biotech from $206.00 to $215.00 and gave the stock a “neutral” rating in a research report on Thursday, February 20th. Finally, Jefferies Financial Group initiated coverage on Krystal Biotech in a research report on Wednesday, March 5th. They issued a “buy” rating and a $245.00 target price for the company. One research analyst has rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, Krystal Biotech has a consensus rating of “Buy” and a consensus target price of $220.00.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).